Drug Search Results
More Filters [+]

PF-05297909

Alternative Names: pf-05297909, pf05297909, pf 05297909
Latest Update: 2012-03-13
Latest Update Note: Clinical Trial Update

Product Description

A novel BACE inhibitorÊ (Sourced from: https://www.diva-portal.org/smash/record.jsf?pid=diva2%3A687867&dswid=-2808)

Mechanisms of Action: BACE Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PF-05297909

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

B3941001

P1

Completed

Healthy Volunteers

2012-02-01

Recent News Events

Date

Type

Title